NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $9.60 +0.14 (+1.48%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$9.67 +0.07 (+0.73%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Gossamer Bio Stock (NASDAQ:GOSS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$9.00▼$9.7750-Day Range$8.43▼$16.3652-Week Range$8.29▼$309.60Volume144,809 shsAverage Volume277,111 shsMarket Capitalization$58.66 millionP/E RatioN/ADividend YieldN/APrice Target$256.00Consensus RatingHold Company Overview Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations. Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling. The therapy is being evaluated for pulmonary arterial hypertension, a serious and progressive disease affecting the blood vessels of the lungs. Seralutinib has advanced into late-stage clinical development, with the company seeking to establish its safety and efficacy as a potential treatment option. The company has also developed additional programs targeting immune and inflammatory diseases, including investigational therapies directed at kinase and other disease-related pathways. Gossamer Bio was founded in 2015 and became a publicly traded company in 2019. Its research and development activities are focused primarily on the United States, while collaborations with international pharmaceutical companies support the potential development and commercialization of its therapies in global markets. Faheem Hasnain, a co-founder of Gossamer Bio, has served as the company’s chairman and chief executive officer. The company’s strategy centers on advancing internally developed therapies through clinical trials and working with strategic partners to expand the reach of successful treatments.AI Generated. May Contain Errors. Read More Gossamer Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreGOSS MarketRank™: 2.14199436317 of 5 starsGossamer Bio scored higher than 43% of companies evaluated by MarketBeat, and ranked 496th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingGossamer Bio has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialGossamer Bio has a consensus price target of $256.00, representing about 2,566.7% upside from its current price of $9.60.Amount of Analyst CoverageGossamer Bio has only been the subject of 4 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gossamer Bio are expected to grow in the coming year, from ($33.00) to ($15.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Gossamer Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.13% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gossamer Bio has recently increased by 30.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Gossamer Bio this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by Insiders4.15% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GOSS Stock News HeadlinesGossamer Bio, Inc. (NASDAQ:GOSS) Stock Has Average Price Target of $256.00 According to BrokeragesOctober 20, 2026 | americanbankingnews.comGossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib RisksOctober 17, 2026 | finance.yahoo.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.October 25 at 1:00 AM | Crypto 101 Media (Ad)Chardan Capital Initiates Coverage on Gossamer Bio (NASDAQ:GOSS)October 15, 2026 | americanbankingnews.comChardan Initiates Gossamer Bio at Buy With $160 Price TargetOctober 13, 2026 | marketscreener.comMGossamer Bio average analyst price target decreased by 40.76% to $80.05October 2, 2026 | msn.comGossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDAOctober 1, 2026 | finance.yahoo.comGossamer Bio Regains Nasdaq Listing Bid Price ComplianceSeptember 30, 2026 | theglobeandmail.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $248.00 at the beginning of 2026. Since then, GOSS shares have decreased by 96.1% and is now trading at $9.60. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) posted its earnings results on Friday, May, 15th. The company reported ($16.00) earnings per share for the quarter, missing analysts' consensus estimates of ($13.60) by $2.40. The company had revenue of $16.96 million for the quarter, compared to analysts' expectations of $4.67 million. Read the conference call transcript. When did Gossamer Bio's stock split? Gossamer Bio shares reverse split on the morning of Friday, September 11th 2026.A 1-80 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 10th 2026. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Tesla (TSLA), Cabaletta Bio (CABA), Precision BioSciences (DTIL), Alector (ALEC) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/15/2026Today10/25/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GOSS's financial health is in the Red zone, according to TradeSmith. GOSS has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GOSS CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees162Year Founded2015Price Target and Rating Average Price Target for Gossamer Bio$256.00 High Price Target$720.00 Low Price Target$80.00 Potential Upside/Downside+2,566.7%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($56.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$170.37 million Net Margins-235.00% Pretax Margin-235.17% Return on EquityN/A Return on Assets-112.04% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$48.47 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value($42.43) per share Price / Book-0.23Miscellaneous Outstanding Shares6,110,000Free Float5,857,000Market Cap$58.66 million OptionableOptionable Beta2.21 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:GOSS) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
